Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeoVisc
- Development stage
- Unknown
- Lead developer
- Fidia Farmaceutici
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraarticular
01
Overview
NeoVisc is an intra-articular hyaluronic acid viscosupplement consisting of highly purified sodium hyaluronate formulated as a sterile gel for injection into the knee joint to relieve pain and improve function in patients with degenerative or mechanical osteoarthritis of the knee. It acts by temporarily replacing and augmenting synovial fluid, restoring its viscosity and elasticity to provide lubrication and shock absorption, and may stimulate endogenous hyaluronan production, thereby reducing pain and improving joint mobility for several months.[1][2][3][9] NeoVisc is marketed in Canada and other markets in multi-injection and single-injection (NeoVisc ONE) regimens and is a naturally derived, biofermented product licensed from Fidia Farmaceutici and commercialized by Aralez Pharmaceuticals Canada, doing business as Miravo Healthcare.[3]
- Brand names
- NeoViscNeoVisc ONENeoVisc+
- Other names
- NeoVisc HA 1.5%
02
Targets
CD44 (CD44 antigen)ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on NeoVisc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoVisc.